New Cancer Drug to be Blocked on NHS

A new breast cancer drug trialled at King's College London is to be blocked from routine NHS access under draft guidance issued by health watchdog NICE.

NICE say that Kadcyla can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay - despite it extending women's lives by almost six months. Patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.

But the decision, if made final later this year, would mean the drug would not be recommended for routine use in England on the NHS and women would have to rely on their doctors' successful application to the Cancer Drugs Fund.